361 related articles for article (PubMed ID: 26773044)
1. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
2. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
3. Critical role for Gab2 in transformation by BCR/ABL.
Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
[TBL] [Abstract][Full Text] [Related]
4. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
5. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
Hsieh MY; Van Etten RA
Blood; 2014 Apr; 123(15):2401-11. PubMed ID: 24464015
[TBL] [Abstract][Full Text] [Related]
6. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.
Dorsey JF; Cunnick JM; Mane SM; Wu J
Blood; 2002 Feb; 99(4):1388-97. PubMed ID: 11830491
[TBL] [Abstract][Full Text] [Related]
8. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
9. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
10. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Million RP; Harakawa N; Roumiantsev S; Varticovski L; Van Etten RA
Mol Cell Biol; 2004 Jun; 24(11):4685-95. PubMed ID: 15143164
[TBL] [Abstract][Full Text] [Related]
11. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Million RP; Van Etten RA
Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H
PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524
[TBL] [Abstract][Full Text] [Related]
13. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
14. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
15. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
16. Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2008 Oct; 283(41):27444-27451. PubMed ID: 18697750
[TBL] [Abstract][Full Text] [Related]
17. Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Gillis LC; Berry DM; Minden MD; McGlade CJ; Barber DL
Leukemia; 2013 Aug; 27(8):1666-76. PubMed ID: 23399893
[TBL] [Abstract][Full Text] [Related]
18. The Philadelphia chromosome in leukemogenesis.
Kang ZJ; Liu YF; Xu LZ; Long ZJ; Huang D; Yang Y; Liu B; Feng JX; Pan YJ; Yan JS; Liu Q
Chin J Cancer; 2016 May; 35():48. PubMed ID: 27233483
[TBL] [Abstract][Full Text] [Related]
19. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
Askmyr M; Ågerstam H; Lilljebjörn H; Hansen N; Karlsson C; von Palffy S; Landberg N; Högberg C; Lassen C; Rissler M; Richter J; Ehinger M; Järås M; Fioretos T
Blood Cancer J; 2014 Dec; 4(12):e269. PubMed ID: 25501026
[TBL] [Abstract][Full Text] [Related]
20. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
